Early and concurrent therapy of dyslipidemia and hypertension: when to start it and how to maintain patient´s good and long-term adherence?
| Autor: | Vladimír Soška |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cardiovascular event
medicine.medical_specialty Combination therapy Blood Pressure 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Diabetes mellitus Internal Medicine Humans Medicine 030212 general & internal medicine Concurrent therapy Intensive care medicine Antihypertensive Agents Dyslipidemias business.industry Combination pharmacotherapy Atherosclerotic cardiovascular disease medicine.disease Blood pressure Cardiovascular Diseases Hypertension Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business Dyslipidemia |
| Zdroj: | Vnitřní lékařství. 67:37-40 |
| ISSN: | 1801-7592 0042-773X |
| Popis: | Treatment of dyslipidemia and hypertension is a key step for reducing the risk of atherosclerotic cardiovascular disease. Dyslipidemia and hypertension often occur in one patient at the same time, so both of these risk factors need to be addressed at the same time. It is better to start therapy before the patient is at high risk of a fatal cardiovascular event. To improve the patients prognosis, it is important not only to achieve the target LDL-cholesterol value and the optimal blood pressure value, but it is also very important (and often more difficult) to maintain the patients good and long-term adherence to established combination pharmacotherapy. For better adherence to long-term therapy also contributes reduction the number of tablets, which can be achieved through the use of a fixed combination of statins and antihypertensive agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|